-
Molecular alterations and emerging targets in castration resistant prostate cancer.
European journal of cancer (Oxford, England : 1990) 20140301
-
Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20130415
-
Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
The Urologic clinics of North America 20121101
-
Metastatic castrate-resistant prostate cancer: dawn of a new age of management.
BJU international 20121001
-
A new era for castrate resistant prostate cancer: a treatment review and update.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20120901
-
Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
BJU international 20120901
-
Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.
Clinical genitourinary cancer 20120901
-
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.
Cancer biology & therapy 20120901
-
Novel and bone-targeted agents for CRPC.
Annals of oncology : official journal of the European Society for Medical Oncology 20120901
-
Management of advanced prostate cancer in senior adults: the new landscape.
The oncologist 20120901
-
Cabazitaxel in metastatic castration-resistant prostate cancer.
Expert review of anticancer therapy 20120901
-
New treatment options for patients with metastatic castration-resistant prostate cancer.
Cancer treatment reviews 20120801
-
Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC).
BJU international 20120801
-
Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer.
P & T : a peer-reviewed journal for formulary management 20120801
-
Managing side effects of the novel taxane cabazitaxel in castrate-resistant prostate cancer.
Clinical journal of oncology nursing 20120601
-
NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
The Lancet. Oncology 20120601
-
Novel molecular targets for the therapy of castration-resistant prostate cancer.
European urology 20120501
-
Cabazitaxel for prostate cancer: patient preparation and ongoing care.
British journal of nursing (Mark Allen Publishing) 20120501
-
The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use.
The oncologist 20120401
-
Castration-resistant prostate cancer: systemic therapy in 2012.
Clinics (Sao Paulo, Brazil) 20120401
-
[Second line therapy for castration-resistant prostate cancer (CRPC)].
Der Urologe. Ausg. A 20120301
-
Advances in the management of high-risk localised and metastatic prostate cancer.
BJU international 20120301
-
Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies.
BJU international 20120301
-
[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients].
Der Urologe. Ausg. A 20120301
-
Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: a practical solution for non-specific binding.
Journal of pharmaceutical and biomedical analysis 20120205
-
[Promising on advanced cancer, several new drugs coming].
Lakartidningen 20120201
-
Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches.
Oncology (Williston Park, N.Y.) 20120101
-
Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling.
Case reports in oncology 20120101
-
[Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France].
Bulletin du cancer 20120101
-
Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatment.
Clinical genitourinary cancer 20111201
-
Novel therapies for metastatic castrate-resistant prostate cancer.
Journal of the National Cancer Institute 20111116
-
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
The oncologist 20111101
-
Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.
Maturitas 20111001
-
Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer.
Asian journal of andrology 20110901
-
Abiraterone and increased survival in metastatic prostate cancer.
The New England journal of medicine 20110825
-
New treatment options for castrate-resistant prostate cancer: a urology perspective.
The Canadian journal of urology 20110801
-
Cabazitaxel: a novel microtubule inhibitor.
Drugs 20110709
-
Overcoming chemotherapy resistance in prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 20110615
-
Optimal management of bone metastases in prostate cancer.
Current oncology reports 20110601
-
Current clinical trials in castrate-resistant prostate cancer.
Current urology reports 20110601
-
[The trend toward development of novel agents based on the mechanism of prostate cancer progression].
Nihon rinsho. Japanese journal of clinical medicine 20110601
-
[Jevtana: clinically significant improvement in survival of patients previously treated with docetaxel].
Revue medicale suisse 20110525
-
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.
European journal of cancer (Oxford, England : 1990) 20110501
-
Contemporary management of metastatic castration-resistant prostate cancer.
Current opinion in urology 20110501
-
Cabazitaxel for the treatment of prostate cancer.
Expert opinion on pharmacotherapy 20110401
-
TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
Future oncology (London, England) 20110401
-
Cabazitaxel: a new drug for metastatic prostate cancer.
Asian journal of andrology 20110301
-
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
Anti-cancer agents in medicinal chemistry 20110301
-
[Castration resistant prostate cancer 2011].
Aktuelle Urologie 20110301
-
Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.
Maturitas 20110201
-
New options for the management of castration-resistant prostate cancer: a case perspective.
Journal of the National Comprehensive Cancer Network : JNCCN 20110201
-
Cabazitaxel for castration-resistant prostate cancer.
Lancet (London, England) 20110108
-
Cabazitaxel for castration-resistant prostate cancer.
Lancet (London, England) 20110108
-
Cabazitaxel for the treatment of castration-resistant prostate cancer.
Future oncology (London, England) 20110101
-
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.
Drug design, development and therapy 20110101
-
Cabazitaxel: filling one of the gaps in the treatment of prostate cancer.
Cancer biology & therapy 20101215
-
Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer.
Clinical genitourinary cancer 20101201
-
A renaissance in the medical treatment of advanced prostate cancer.
Oncology (Williston Park, N.Y.) 20101201
-
Cabazitaxel in prostate cancer: stretching a string.
Lancet (London, England) 20101002
-
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Lancet (London, England) 20101002
-
Cabazitaxel, a new taxane with favorable properties.
Drugs of today (Barcelona, Spain : 1998) 20101001
-
Cabazitaxel, a taxane for men with hormone-refractory metastatic prostate cancer.
Oncology (Williston Park, N.Y.) 20101001
-
New treatments for metastic prostate cancer.
The Medical letter on drugs and therapeutics 20100906
-
Cabazitaxel.
Nature reviews. Drug discovery 20100901
-
New taxane treats advanced prostate cancer.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100801
-
Castration refractory prostate cancer: cinderella finally comes to the ball.
Onkologie 20100101
-
Critical appraisal of cabazitaxel in the management of advanced prostate cancer.
Clinical interventions in aging 20100101